Satisfied with DLENX (monthly) Asset manager:
Luz Padilla (Started: Apr 6, 2010) Dollar denominated decisions by Ms Padilla continue to pay-off.
http://www.doublelinefunds.com/pdf/3-31-15_Div_Payment_Schedule.pdf
Not so much.
MAINX Div Total **
03/19/2015 10.34 0.0000 0.0009 0.0009
**However, primarily because of tax rules related to currency losses from sales of the
Fund’s foreign bond holdings, the amount of the Fund’s income distribution for
Q115 was impacted http://us.matthewsasia.com/resources/docs/pdf/literature/Strategic-Income-Fund-Distribution-QA-1Q2015.pdf
First I owned.Bought for good preservation record.DHGAX
(From Dreyfus) :Ranked #1 by U.S. News & World Report
The fund was ranked as the top fund in U.S. News & World Report’s “Best Funds” list among all funds within the World Bond category, which contains funds that invest 40% or more of their assets in foreign bonds, including developed and emerging markets. U.S. News & World Report’s categorization was based on Morningstar’s World Bond description.
Rankings as of March 4, 2015. Past performance is no guarantee of future results.
https://public.dreyfus.com/
Dreyfus/Standish Global Fixed Income Fund - Class A1
DHGAX Div 0.0830
S T Gain 0.0308
L T Gain 0.0900
Total 0.2038 03/30/15 Price 22.05 Quarterly

FYI:
Regards,
Ted
WSJ Slant:
http://www.wsj.com/articles/u-s-stock-futures-trade-lower-1427890171
Bloomberg Slant;
http://www.bloomberg.com/news/articles/2015-04-01/s-p-500-futures-slide-in-early-trading-after-quarterly-advance
Reuters Slant:
http://www.reuters.com/article/2015/04/01/us-markets-stocks-us-idUSKBN0MS44S20150401
MarketWatch Slant;
http://www.marketwatch.com/story/stock-futures-lower-after-dramatic-dive-in-asia-trading-hours-2015-04-01/print
WSJ Markets At A Glance:
http://markets.wsj.com/us
Sector Tracker:
http://www.sectorspdr.com/sectorspdr/tools/sector-tracker
Current Futures:
http://finviz.com/futures.ashx

FYI: The price of a bushel of corn for May delivery tumbled during the last day of the quarter by almost 5 percent to $3.756. The move was caused by the corn supply in the Unites States coming in much higher than expected, even after the government pegged its inventory in June at its highest level in 28 years.
The 7.75 billion bushels' stockpile, as of March 1, is 11 percent higher than a year ago, according to the U.S. Department of Agriculture. The reading outpaced economists' estimates of an 8.6 percent increase and is the highest on record at this date since 1987.
Regards,
Ted
http://www.marketwatch.com/story/commodity-funds-continue-to-struggle-2015-04-01-12463348/print

Glad I read this synopsis... I think I'll be taking advantage of the Institutional Shares - No Minimum Investment being offered to direct RiverPark investors. It seems opportune to put a small deposit in just to have the I shares. And I emphasis 'small'. I'd like to see current holdings and a little history to see if it matches my temperament before venturing further.
@Derf: Yes, the NAV on RPHYX/RPHIX and RSIVX/RSIIX have dropped, but if HY is yielding 3% and SI is doing 5-7%, I feel I can take a hit on the asset value and offset it with the interest yield while I keep my fingers crossed. My 'Total Return' is still positive and it's better than Money Market or banks.

Mulder,
Since you are considering VASVX, you might want to look into VMVAX for the following reasons.
1. VMVAX is more of pure mid cap value fund. 36% of VASVX is large cap.
2. VIMAX has superior 1 and 3 year returns and while Admiral shares have not not been in existence for 5 years, VMVIX has better 5 year returns.
3. VMVAX has an expense ratio of 0.09%. VASVX has an expense ratio of 0.41%.
While I think VASVX is a fine actively managed fund, I believe that is primarily attributable to Jim Barrow, its lead manager and secondarily, Mark Giambrone, both of Barrow, Hanley, Mewhinney & Strauss. Jim will be 75 in the next few months and in preparation of his eventual retirement, Vanguard has has added two fund advisers (Donald Smith & Co and Pzena Investment Management), which I feel dilutes the good ideas from Barrow and Giambrone.
Mona

Monthly, with 1 and 3yr trailing.
http://www.capitalspectator.com/major-asset-classes-march-2015-performance-review/

I hold Perkins MidCap Value Fund (JMCVX) in my IRA at Fidelity. I have been with this fund for almost a decade. I have seen the good side and now seeing the bad side.
I have finally decided to bail out of this MidCap Value fund (only time will tell if my timing is bad :) and narrowed by choices to one of
following:
- Harbor MidCap Value NTF at Fidelity (HIMVX)
- Fidelity MidCap Value (FSMVX)
- Vanguard Selected Value (VASVX, not a NTF at Fidelity)
Since, I hold a large amount of this fund in Rollover IRA, I will be planning to liquidate this fund 5% at a time, so that I can then divert
the proceeds to one of the above fund monthly. I do not want to liquidate all at once and be in cash and I do not want to put a big lumpsump into
one of the above funds in one transaction.
If you were in my shoes, what would be your choice from above? Also, any other Midcap value funds to consider.
Thanks
Mulder

FYI: Below is a look at the performance of various asset classes in Q1 2015 using key ETFs traded on US exchanges. For the quarter, the S&P 500 SPY ETF gained 0.43%, marking its 9th consecutive quarter of gains. While the S&P 500 gained, the Dow 30 (DIA) fell 0.17%.
Outside of the large cap SPY and DIA, other equity indices did much better. The Nasdaq 100 (QQQ) gained 2.28%, while the Mid Cap 400 (IJH) rose 4.96% and the Small Cap 600 (IJR) gained 3.48%. Mid Cap and Small Cap growth
Regards,
Ted
https://www.bespokepremium.com/think-big-blog/bespokes-etf-matrix-of-q1-asset-class-performance/

As for the E.R. of this fund, given the shorting and leverage, coming from another company this kind of fund could easily have an E.R closer to 1.75-2.

According to the latest prospectus, ACDJX has an actual, what-the-investor-actually- pays ER of 1.81%.
Kevin

Well, there ya go lol. Thanks to kevin for the research.

FYI: Gundlach’s main mutual fund, the $45.6 billion DoubleLine Total Return Bond Fund, is at the top of its class as it marks its fifth anniversary on April 6. It’s bested all 235 competitors in the U.S. intermediate bond fund category since inception, according to Morningstar Inc. In the previous five years, the TCW Total Return Bond Fund then-managed by Gundlach ranked second
Regards,
Ted
http://www.bloomberg.com/news/articles/2015-04-01/gundlach-tops-peers-at-five-years-as-caution-belies-image

@scott oh, stop with the maybe-baby "forward p/e" crap. You know it is predictive of nothing; you're just pumpin' your book, aren't you? :)

Personally, I share a lot of what I do on this board and when I do, I give reasoning. I do own GILD and other healthcare stocks and a few differerent funds. As for GILD in particular, you have a company that had $24.9B in revenue in 2014, a 127% increase over 2013. Starts a dividend soon, $15B buyback, has a significant pipeline and yet, is trading at a 13 p/e. I think the current valuation is cheap and discounts a lot of the pipeline. It is likely in part to the idea of competition and pricing for their HEP-C treatments coming down, but Abbvie's competing Viekira Pak has been disappointing in terms of numbers and in terms of pricing coming down (also partly due to controversy over prices, although the question becomes how much would a liver transplant be), I think that's largely been discounted already.
I don't think there is that much genuine value in the market, but that's an example of something that I personally see as a pretty terrific value. Plus, the CEO won M*'s CEO of the year last year, although I'm still not sure whether or not to see that as a good or bad thing. I was impressed with how Gilead handled the Express Scripts move to the cheaper Abbvie product, and added on that downturn and have continued to add.
I actually think the large cap biotechs are still a good choice for those who can tolerate day-to-day volatility. They held up nicely in 2008, as well. As I've said, I do think a lot of the smaller biotechs have rallied on the promise of their pipeline and that's why when dealing with this sector, I'd rather either pick specific stocks or have actively managed funds or both instead of an index.
Lastly, I continue to like health care from the standpoint of I tend to focus investments on needs instead of wants. I sleep better at night with investments that at least heavily lean towards things people need versus things where I have to worry about what may be "the next big thing".
As for the E.R. of this fund, given the shorting and leverage, coming from another company this kind of fund could easily have an E.R closer to 1.75-2. I'm not saying that it's not inexpensive in a general sense, I'm saying that it could easily be more expensive, given what it is.

FYI: They’re cheap, most investors are scared to death of them, and yet they have been slowly grinding higher throughout 2015. Are emerging markets — and the iShares MSCI Emerging Markets ETF (NYSEARCA:EEM) — worth owning as we jump into the second quarter?
Regards,
Ted
http://investorplace.com/2015/03/eem-etf-consider-emerging-markets/print
M* Snapshot Of EEM: http://www.morningstar.com/etfs/ARCX/EEM/quote.html
EEM Is Ranked #21 In The (EM) ETF Fund Category By U.S. News & World Report:
http://money.usnews.com/funds/etfs/emerging-markets-funds/ishares-msci-emerging-markets-etf/eem

FYI: Retirement-oriented managers take top awards; other victors include American Funds, Oakmark and Lord Abbett.
Regards,
Ted
http://www.investmentnews.com/article/20150331/FREE/150339978?template=printart
Reuters Slant:
http://www.reuters.com/article/2015/04/01/funds-lipperawards-idUSL2N0WX1NN20150401

RIP:
Elizabeth Bramwell, the founding manager of Gabelli & Co.’s growth mutual fund who quit to form her own asset-management firm and became a beacon for women in the field, has died. She was 74.
Regards,
Ted
http://www.bloomberg.com/news/articles/2015-03-09/elizabeth-bramwell-ex-gabelli-growth-fund-manager-dies-at-74

As of the 2014 close, M* shows this fund as top-heavy in LCG, yet it has 15% in microcap as well. It was circa 30% short, and (leveraged) 125% long, with a very high e.r.=1.48%. And this is one of your "core holdings"? Is that what you meant to say?

I recently sold my spiff (special investment position) off that I opened in October of 2014 with about an 8.3% gain plus dividends. Had I sold a few days earlier I'd have had a gain of about 10.4%. I chose to exit with respectable gains rather than to wait and watch them evaporate as we approach and enter 1Q2015 earnings reporting season as I believe earnings are going to disappoint.

@openice: Thanks for the info ! What was not to be.
Regards,
Ted
http://www.sec.gov/Archives/edgar/data/1282693/000089418914004958/baird-greenhouse_485a.htm

MAPOX= .50 cents for 1Q. Inline with expectations. I've got 3 others which pay MONTHLY. (DLFNX, PREMX and PRSNX.) SFGIX pays in June and December, and is making a mini-comeback in the last couple or few days, on its way to $12.00/share. Still some distance to cover, there... And my others pay (hopefully) only at end-of-year: MSCFX, TRAMX, PRWCX, PRASX. Wifey's 403b did pay a "supplemental" tiny dividend in March. NAESX. Looking at their pay-out history, that fund makes a habit of doing that: bigger pay-out in December, then a tiny little something in March. Ted informed us of the March pay-out in 2015, originally, if memory serves me.

I'm always a little unsure about how to think about asset allocation when you read about global market cap numbers. If you use MSCI indices to estimate global market cap the US is more than 50% of global market cap whereas Bloomberg data says the US is only 36%. The difference, I believe, is that MSCI's number only include free-floating market cap whereas others include "everything". For instance, I think that means MSCI excludes China's A shares (so far), and they don't include Saudi Arabia, which Bloomberg includes.
All of that is fine and well, but when we think about our portfolios and asset allocation, should we think about the US being 50+% of global market cap or only 36%? Or would it be better to use GDP numbers?